Mobile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with...

Update Il y a 5 ans
Reference: EUCTR2009-013442-86

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the antiviral efficacy (sustained virologic response; SVR) of 48 weeks of GS-9190 versus placebo when administered in combination with 48 weeks of peginterferon alfa 2a (PEG) and ribavirin (RIBA)

Inclusion criteria

  • Chronic hepatitis C virus infection

Links